News

With new leadership and a Nasdaq relisting plan, the iconic brand is betting on women’s health and weight loss drugs to stage ...
Novo Nordisk is a global diabetes and weight loss leader with strong long-term growth prospects. Read why NVO stock is a ...
Analyst initiates coverage of WeightWatchers with a buy rating after bankruptcy reemergence. IPO hot streak continues.
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...